Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JNPR stock price vs ELV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ELV's multiple
Needs ELV P/E.
Implied fair value · at JNPR's multiple
Needs JNPR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
JUNIPER NETWORKS, INC. · implied price per share
Bear
$16.15
Base
$19.35
Bull
$23.51
ELEVANCE HEALTH, INC. · implied price per share
Bear
$158.07
Base
$203.66
Bull
$263.02
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CISCO SYSTEMS, INC.
JNPR vs CSCO
Dell Technologies Inc.
JNPR vs DELL
Palo Alto Networks Inc
JNPR vs PANW
Fortinet, Inc.
JNPR vs FTNT
VERISIGN INC/CA
JNPR vs VRSN
Match Group, Inc.
JNPR vs MTCH
UnitedHealth Group Incorporated
JNPR vs UNH
CVS Health Corporation
JNPR vs CVS
HUMANA INC
JNPR vs HUM
CENTENE CORP
JNPR vs CNC
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNPR can stabilize revenue growth and sustain its current margin profile, then a selective relative-value position may be justified because the DCF range of $8.86-$11.98 sits below ELV-implied $14.26 valuation point, but the case weakens if growth remains negative.
Based on the provided ELV-implied range, JNPR's implied P/E price of $14.26 sits above the midpoint of ELV-derived valuation outcomes, but the comparison is limited because JNPR has no reported P/E, P/S, or EV multiples in the dataset. The DCF range of $8.86 to $11.98 is meaningfully below ELV-implied point estimate, suggesting the current valuation framework is somewhat divided.
Supporting Metrics
